Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide compound contains semaglutide—the active pharmaceutical ingredient—plus excipients including sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, and water for injection. The FDA-approved branded formulations (Ozempic, Wegovy) share similar active ingredients but are manufactured under strict pharmaceutical standards, while compounded versions from 503A pharmacies use approved USP/NF components under state pharmacy regulation.

Understanding what's actually in your semaglutide formulation matters because excipients affect stability, injection comfort, and how your body processes the medication. At PlexusDx, we believe informed patients who understand their treatment components can have more productive conversations with their providers about whether compounded semaglutide fits their clinical picture and genetic predispositions.

The Active Ingredient: Semaglutide and Its Mechanism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist—a 31-amino-acid peptide that mimics the naturally occurring hormone GLP-1. It binds to GLP-1 receptors in the pancreas and brain to increase insulin secretion, slow gastric emptying, and reduce appetite. Clinical trials demonstrate semaglutide reduces HbA1c by 1.0–1.8% in type 2 diabetes and body weight by 5–10% in weight management studies.

The semaglutide molecule itself is identical whether produced by Novo Nordisk for Ozempic/Wegovy or synthesized by a compounding pharmacy using USP-grade bulk powder. The pharmacological action remains the same; differences lie in formulation stabilizers, preservatives, and manufacturing oversight rather than the active peptide itself.

Excipients and Formulation Components: What Else Is in the Vial

Beyond semaglutide, compounded formulations contain several excipients that serve critical functions. These include sodium phosphate buffer salts (to maintain pH stability), sodium chloride (to maintain osmolarity), metacresol or phenol (preservatives in multi-dose vials), and water for injection. Each component is selected to keep the peptide stable and safe for subcutaneous injection.

Component Purpose Typical Concentration
Semaglutide Active GLP-1 agonist 1.34 mg/mL (0.5 mg/0.375 mL pen dose)
Sodium phosphate dibasic Buffer system for pH stability 1.42 mg/mL
Sodium phosphate monobasic Buffer system for pH stability 1.42 mg/mL
Sodium chloride Osmolarity adjustment 5.85 mg/mL
Metacresol or phenol Preservative in multi-dose vials 1.5 mg/mL or 3 mg/mL
Water for injection Solvent and vehicle Remainder to final volume

Compounded vs. Branded Formulation: Where Differences Matter Clinically

Branded semaglutide (Ozempic, Wegovy) undergoes FDA approval under the New Drug Application (NDA) pathway with defined manufacturing, stability testing, and pharmaceutical oversight. Compounded semaglutide from 503A pharmacies follows USP chapters and state pharmacy law but does not undergo FDA pre-approval. Both use semaglutide bulk powder sourced from pharmaceutical suppliers, but manufacturing environments and quality-control protocols differ.

For patients, this distinction means branded products carry FDA-tested stability data and formal adverse event monitoring, while compounded options may offer cost savings and access to qualified providers in states with robust compounding oversight. Neither formulation type guarantees superior clinical outcomes; individual response depends on genetics, lifestyle, baseline health markers, and adherence rather than formulation alone.

Who Should Consider Semaglutide and How Genetic Predisposition Adds Context

Semaglutide is indicated for type 2 diabetes management and chronic weight management in adults with obesity or weight-related conditions. However, not everyone responds equally. Clinical response varies based on genetics, baseline metabolic rate, gut hormone sensitivity, and GLP-1 receptor expression. Some patients experience robust appetite suppression; others require dose titration or combination therapy to achieve desired glycemic or weight outcomes.

Certain genetic variants in the GLP-1 receptor (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), and appetite-regulation genes like FTO and MC4R may influence individual semaglutide efficacy and side-effect tolerance. While genetic predisposition does not predict exact medication response, it can help contextualize why one patient thrives on semaglutide while another requires adjustment or alternative approaches. Discussing genetic insights with your provider supports more personalized decision-making.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 peptide pathways (GLP1R, GIPR, FTO, MC4R) to may help provide context around how your body's genetic landscape relates to GLP-1 agonist sensitivity and metabolic response. This insight should be interpreted with a qualified healthcare provider as part of a comprehensive clinical assessment—not as a definitive predictor of semaglutide success or failure.

Understanding what's in your semaglutide formulation combined with your genetic predispositions supports a more complete picture. The Precision Peptide Genetic Test reveals genetic variations associated with peptide pathway function, but these predispositions represent risk factors or tendencies, not guarantees. Individual response still depends on lifestyle, dose titration, medication adherence, and overall health status.

When discussing semaglutide options with your provider, sharing both formulation transparency (what excipients are present) and genetic context (if available through testing) allows for more informed, individualized conversations. This dual approach supports shared decision-making about whether compounded semaglutide, branded alternatives, or other peptide therapies best align with your clinical needs and biological predispositions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves